Properties (72)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Otsuka_Pharmaceutical
2014 by Otsuka Pharmaceutical |
| gptkbp:advertising |
gptkb:Jane_Doe
targeted marketing campaigns |
| gptkbp:businessModel |
focused on specialty pharmaceuticals
|
| gptkbp:CEO |
gptkb:Brett_P._Monia
|
| gptkbp:clinicalTrials |
neurological disorders
published in peer-reviewed journals multiple ongoing presented at conferences I, II, and III conducted Phase 3 for new indications monitored for efficacy and safety. ongoing for new therapies thousands enrolled across_the_United_States conducted_for_Nuedexta |
| gptkbp:collaborations |
various academic institutions
with other pharmaceutical companies |
| gptkbp:community_engagement |
support for patient advocacy groups
|
| gptkbp:community_outreach |
educational initiatives
|
| gptkbp:employees |
approximately 200
|
| gptkbp:enrollment |
focused on adults
|
| gptkbp:financials |
held quarterly
|
| gptkbp:focus_area |
central nervous system disorders
|
| gptkbp:focusArea |
central nervous system disorders
|
| gptkbp:founded |
1980
|
| gptkbp:founder |
Dr. A. Thomas McGowan
M._Anthony_(Tony)_DeMarco |
| gptkbp:funding |
from government and private sources
|
| gptkbp:future_plans |
expand product offerings
|
| gptkbp:headCoach |
approximately 200 employees
|
| gptkbp:headquarters |
gptkb:Aliso_Viejo,_California
|
| gptkbp:healthcare |
available_for_Nuedexta
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avanir Pharmaceuticals
|
| gptkbp:investmentFocus |
available on website
in R&D for drug development |
| gptkbp:is_part_of |
gptkb:Otsuka_Group
|
| gptkbp:market |
gptkb:United_States
|
| gptkbp:mission |
improving the lives of patients with neurological conditions
|
| gptkbp:notableEvent |
Nuedexta
|
| gptkbp:notableFeature |
Nuedexta
Zenvia |
| gptkbp:partnerships |
gptkb:Otsuka_Pharmaceutical
various academic institutions with healthcare providers for research purposes |
| gptkbp:productLine |
includes several investigational drugs
|
| gptkbp:products |
Nuedexta_for_pseudobulbar_affect
Zenvia_for_agitation_in_Alzheimer's_disease |
| gptkbp:publications |
authored by researchers
|
| gptkbp:regulatoryCompliance |
for new drugs
FDA_approval_for_Nuedexta |
| gptkbp:research |
gptkb:Dr._John_Smith
|
| gptkbp:research_areas |
neurology
psychiatry |
| gptkbp:research_focus |
treatment of neurological diseases
|
| gptkbp:researchFocus |
neurodegenerative diseases
|
| gptkbp:revenue |
approximately $100 million
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:social_responsibility |
initiatives in healthcare access
|
| gptkbp:specializesIn |
neurology
|
| gptkbp:stockExchange |
AVNR
|
| gptkbp:subsidiary |
gptkb:Otsuka_America_Pharmaceutical
|
| gptkbp:targetMarket |
Nuedexta_in_2010
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:training |
implemented for staff development
|
| gptkbp:type |
Public company
public company |
| gptkbp:website |
www.avanir.com
|